Amarin Corp Plcuk (AMRN) Gains from Sales and Divestitures (2013 - 2025)
Amarin Corp Plcuk (AMRN) posted quarterly Gains from Sales and Divestitures of $8.5 million for Q4 2025, up 121.78% YoY from $3.9 million in Q4 2024, and up 121.78% sequentially from $3.9 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Gains from Sales and Divestitures (2013 - 2025) Analysis & Trends
Amarin Corp Plcuk has disclosed Gains from Sales and Divestitures across 12 years of filings, most recently posting $8.5 million for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures rose 121.78% year-over-year to $8.5 million; the TTM figure through Dec 2025 stood at $8.5 million (up 121.78% YoY), while the FY2025 annual figure was $8.5 million, up 121.78% from the prior year.
- Gains from Sales and Divestitures climbed to $8.5 million in Q4 2025, from $3.9 million in the prior quarter.
- Over the last five years, Gains from Sales and Divestitures for AMRN reached as high as $8.5 million in Q4 2025 and fell as low as $1.9 million in Q4 2022.
- The 5-year median for Gains from Sales and Divestitures is $4.1 million (2021), against an average of $4.5 million.
- Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures tumbled 52.18% — and 2025, when it jumped 121.78%.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $4.1 million in 2021, then plunged by 52.18% to $1.9 million in 2022, then soared by 119.02% to $4.2 million in 2023, then slipped by 9.34% to $3.9 million in 2024, then soared by 121.78% to $8.5 million in 2025.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $8.5 million, $3.9 million, and $4.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.54 Mn |
| Dec 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 4.06 Mn |
| Dec 31, 2021 | 4.06 Mn |
| Dec 31, 2020 | 2.51 Mn |
| Dec 31, 2020 | 2.51 Mn |
| Dec 31, 2019 | 3.97 Mn |
| Dec 31, 2019 | 3.97 Mn |
| Dec 31, 2018 | 4.61 Mn |
| Dec 31, 2018 | 4.61 Mn |
| Dec 31, 2017 | 2.18 Mn |
| Dec 31, 2017 | 2.18 Mn |
| Dec 31, 2016 | 1.85 Mn |
| Dec 31, 2016 | 1.85 Mn |